NBY NovaBay Earnings per share for the last twelve months

NBY (NovaBay Pharmaceuticals Inc.) - company brandmark

How can one manage the pressure of price wars and the risk of losing loyalty in the over-the-counter segment? The rolling 12-month EPS reflects current dynamics, where the parameter has stabilized at -7.43. The stable income of NovaBay Pharmaceuticals (NBY) is based on patient habits regarding ophthalmic antiseptics, while Avenova's high reputation among US physicians guarantees business resilience.

NBY NovaBay Pharmaceuticals Earnings per share for the last 12 months (07/04/2022 - 04/18/2026)

NovaBay - analytical breakdowns and key metrics (NBY)

- stock price and consensus target price:
Analysis of all company metrics:NovaBay Pharmaceuticals Inc. (NBY)
Flagship merchandise of NovaBay Pharmaceuticals Inc.

When screening for issuer reliability, analyzing the actual capital growth per share becomes key. This metric is calculated as the ratio of total annual net income to the average number of shares outstanding. For NovaBay Pharmaceuticals (NBY), this calculation reflects the efficiency of scaling ophthalmology product sales through contract manufacturing. The current annual net income per share confirms the business's ability to generate profit without capital expenditures on manufacturing plants.